Keratin 19 (D7F7W) Rabbit Monoclonal Antibody (BSA and Azide Free)#13597,Cell Signaling Technology (CST),13597

Keratin 19 (D7F7W) Rabbit Monoclonal Antibody (BSA and Azide Free) detects endogenous levels of keratin 19 protein.

Host

Rabbit

Reactivity

Human

Platform ID

BAB296735643

Cell Signaling Technology (CST)

Headquarters

3 Trask Lane Danvers, MA 01923

Contact

Tel: 877-616-2355,978-867-2388
Fax: 877-616-2355

Product Specifications
Scientific Background
Synonyms

Specifications

NameKeratin 19 (D7F7W) Rabbit Monoclonal Antibody (BSA and Azide Free)#13597
Cat. No.13597
Accession NumberP08727
Gene ID (Entrez)08727, 3880
HostRabbit
SensitivityEndogenous
ReactivityHuman
Molecular Weight41
ImmunogenIgG
FormulationThis product is the carrier free version of product #13092. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol.This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, pleasecontact us. Optimal dilutions/concentrations should be determined by the end user.BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity.
StorageStore at -20°C.This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles.A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance.
Regulatory StatusResearch Use Only

Scientific Background

Keratins (cytokeratins) are intermediate filament proteins that are mainly expressed in epithelial cells. Keratin heterodimers composed of an acidic keratin (or type I keratin, keratins K9-K28) and a basic keratin (or type II keratin, keratins K1-K8 and K71-K80) assemble to form filaments. Keratin isoforms demonstrate tissue- and differentiation-specific profiles that make them useful as research and clinical biomarkers (1,2).Dysregulation/mutations in keratin genes can lead to a variety of disorders affecting the skin, hair, nails, and other epithelial tissues (3). While expression of keratins can be variable, immunohistochemical staining of keratins is widely used to help in the identification and classification of epithelial tumors, and may also provide prognostic information.Keratins 8 and 18 (K8/K18) are expressed in simple epithelia of normal tissue, as well as in adenocarcinomas of the breast, lung, ovary, and gastrointestinal tract. Keratin 17 is expressed in basal keratinocytes of stratified epithelia, hair follicles, and sebaceous glands. Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development (4). Keratin 14 (K14) is expressed in basal cells of stratified epithelia, and in basal-like subtypes of breast cancer and squamous cell carcinomas. Keratin 19 (K19) is expressed in glandular epithelia, including the liver, gallbladder, and pancreas, as well as in adenocarcinomas of the breast, thyroid, and bile duct. Keratin 20 (K20) is expressed in gastrointestinal epithelium, urothelium, and Merkel cells in the skin, as well as in colorectal carcinomas and some urothelial carcinomas. Keratin 5/6 (K5/6) is expressed in basal cells of stratified epithelia, including the skin, prostate, and breast, as well as in basal-like breast cancers, squamous cell carcinomas, and some lung carcinomas. Keratin 7 (K7) is expressed in glandular epithelia, such as those in the lung, breast, and female reproductive tract, as well as in adenocarcinomas of the lung, breast, and ovary (5,6).Keratins, particularly K8, K18, and K19, serve as biomarkers for identification of circulating tumor cells (CTCs) (5).Post-translational modifications, including phosphorylation, acetylation, ubiquitylation, sumoylation, glycosylation, and transamidation, have been shown to affect the functions of keratins in normal and disease states (6). Understanding the molecular mechanisms underlying these PTMs may provide insights into cancer pathogenesis.Chang, L. and Goldman, R.D. (2004)Nat Rev Mol Cell Biol5, 601-13.Schweizer, J. et al. (2006)J Cell Biol174, 169-74.Sarma, A. (2022)Int J Biol Macromol219, 395-413.McGowan, K.M. and Coulombe, P.A. (1998)J Cell Biol143, 469-86.Werner, S. et al. (2020)Mol Aspects Med72, 100817.Dmello, C. et al. (2019)J Biosci44, 33.Alternate Names40-kDa keratin intermediate filament; CK-19; CK19; cytokeratin 19; Cytokeratin-19; K19; K1C19; K1CS; keratin 19; keratin 19, type I; Keratin-19; Keratin, type I cytoskeletal 19; keratin, type I, 40-kd; KRT19; MGC15366

Synonyms

40-kDa keratin intermediate filament; CK-19; CK19; cytokeratin 19; Cytokeratin-19; K19; K1C19; K1CS; keratin 19; keratin 19, type I; Keratin-19; Keratin, type I cytoskeletal 19; keratin, type I, 40-kd; KRT19; MGC15366

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.